AGEN1884

DRUG3 trials

Sponsors

Agenus Inc., The University of Texas Health Science Center at San Antonio

Conditions

AngiosarcomaCervical CancerUrinary Bladder Neoplasms

Phase 2

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

TerminatedNCT03894215

Agenus Inc.Cervical Cancer

Start: 2019-06-01End: 2025-03-26Updated: 2026-03-27

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

TerminatedNCT04430036

The University of Texas Health Science Center at San AntonioUrinary Bladder Neoplasms

Start: 2020-10-14End: 2022-03-14Updated: 2024-04-04

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

WithdrawnNCT04607200

Agenus Inc.Angiosarcoma

Start: 2021-02-28End: 2021-09-13Updated: 2022-01-11

Related Papers

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

Journal of Clinical Oncology2021-12-21169 citations

RaPiDS (GOG-3028): Randomized Phase II Study of Balstilimab Alone or in Combination with Zalifrelimab in Cervical Cancer

Future Oncology2021-08-1928 citations

Antibodies to watch in 2020.

2020-01-01328 citations